ErVimmune
Last verified 2026-05-20. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $21.6Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2023-06-01attributed |
| Founded | 2017 |
| Headquarters | Lyon, France |
| Industry | biotech |
| Stage | unknown |
| Website | ervimmune.com |
Therapeutic cancer vaccines and T-cell immunotherapies targeting endogenous retrovirus antigens (formerly ErVaccine Technologies)
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-06-01 | grant | $2.7M | undisclosed |
Detected tech stack
PHP 8.3, FitVids.JS 4.22.2, SVG Support, jQuery Migrate 3.4.1, Easy Pie Chart, Divi 4.22.2, Zepto, MySQL, wordpress ., jquery 3.
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $21.6M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | ervimmune.com, read 2026-05-20 |
| Description | self-reported | ervimmune.com, read 2026-05-20 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.